Oral ketamine vs placebo in patients with cancer-related neuropathic pain

Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited.1 Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropat...

Full description

Bibliographic Details
Main Authors: Fallon, Marie T., Wilcock, Andrew, Kelly, Caroline A., Paul, James, Lewsley, Liz-Anne, Norrie, John, Laird, Barry J. A.
Format: Article
Language:English
Published: American Medical Association 2018
Online Access:https://eprints.nottingham.ac.uk/51161/
_version_ 1848798431857868800
author Fallon, Marie T.
Wilcock, Andrew
Kelly, Caroline A.
Paul, James
Lewsley, Liz-Anne
Norrie, John
Laird, Barry J. A.
author_facet Fallon, Marie T.
Wilcock, Andrew
Kelly, Caroline A.
Paul, James
Lewsley, Liz-Anne
Norrie, John
Laird, Barry J. A.
author_sort Fallon, Marie T.
building Nottingham Research Data Repository
collection Online Access
description Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited.1 Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropathic pain. A randomized trial of oral ketamine for cancer-related neuropathic pain has been called for, and the present trial addresses that need.
first_indexed 2025-11-14T20:19:40Z
format Article
id nottingham-51161
institution University of Nottingham Malaysia Campus
institution_category Local University
language English
last_indexed 2025-11-14T20:19:40Z
publishDate 2018
publisher American Medical Association
recordtype eprints
repository_type Digital Repository
spelling nottingham-511612018-04-17T04:27:49Z https://eprints.nottingham.ac.uk/51161/ Oral ketamine vs placebo in patients with cancer-related neuropathic pain Fallon, Marie T. Wilcock, Andrew Kelly, Caroline A. Paul, James Lewsley, Liz-Anne Norrie, John Laird, Barry J. A. Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited.1 Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropathic pain. A randomized trial of oral ketamine for cancer-related neuropathic pain has been called for, and the present trial addresses that need. American Medical Association 2018-04-05 Article PeerReviewed application/pdf en cc_by https://eprints.nottingham.ac.uk/51161/1/jamaoncology_Fallon_2018_ld_180004.pdf Fallon, Marie T., Wilcock, Andrew, Kelly, Caroline A., Paul, James, Lewsley, Liz-Anne, Norrie, John and Laird, Barry J. A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain. JAMA Oncology . ISSN 2374-2437 https://doi.org/10.1001/jamaoncol.2018.0131 doi:10.1001/jamaoncol.2018.0131 doi:10.1001/jamaoncol.2018.0131
spellingShingle Fallon, Marie T.
Wilcock, Andrew
Kelly, Caroline A.
Paul, James
Lewsley, Liz-Anne
Norrie, John
Laird, Barry J. A.
Oral ketamine vs placebo in patients with cancer-related neuropathic pain
title Oral ketamine vs placebo in patients with cancer-related neuropathic pain
title_full Oral ketamine vs placebo in patients with cancer-related neuropathic pain
title_fullStr Oral ketamine vs placebo in patients with cancer-related neuropathic pain
title_full_unstemmed Oral ketamine vs placebo in patients with cancer-related neuropathic pain
title_short Oral ketamine vs placebo in patients with cancer-related neuropathic pain
title_sort oral ketamine vs placebo in patients with cancer-related neuropathic pain
url https://eprints.nottingham.ac.uk/51161/
https://eprints.nottingham.ac.uk/51161/
https://eprints.nottingham.ac.uk/51161/